

# **Mariacristina Parravano, M.D.**

curriculum vitae

**Researcher at IRCCS Fondazione Bietti, Rome, Italy  
(2004-Present)**

Via Livenza n 3  
Rome, Italy, 00198  
(+39) 0685356727

## **Professional Appointments**

***IRCCS Fondazione Bietti, Rome, Italy***  
Head, Medical Retina Unit

***University of Rome Tor Vergata***  
***Rome, Italy***  
Contract Professor Ophthalmology Residency: Retinal Pathologies

***Italian Ministry of Health***  
Research workflow Responsible of IRCCS-Fondazione Bietti Retina projects

## **Previous Professional Appointments**

***IRCCS-Fondazione Bietti, Rome, Italy***  
2004-Present Researcher in the Medical Retina Unit

***Complesso Ospedaliero S. Giovanni-Addolorata, IRCCS-Fondazione Bietti, Rome, Italy***  
2008-2017 Consultant in the Maculopathy Center

***IRCCS-Fondazione Bietti, Rome, Italy***  
2015-Present Head of Medical Retina Unit

***Italian Ministry of University***

2017 Associate Professor, Ophthalmology

***Policlinico A. Gemelli, Rome, Italy***

Speaker II Level University Master in “Vitreoretinal pathologies: from the diagnosis to medical and surgical treatment”. “Medical Retina Course II” (3 hours). Title: WetAMD etipathogenesis and diagnosis. 18 March 2011

**Education**

***University of Campus BioMedico  
Rome, Italy***

1994-2000: M.D.

**Postgraduate Training**

***University of Rome Tor Vergata  
Rome, Italy***

2001-2004: Resident in Ophthalmology

***Moorfields Eye Hospital***

*London, UK*

2004: Observer in Medical Retina Unit (Prof A. Bird)

***IRCCS-Fondazione Bietti***

*Rome, Italy*

2006-2007 Fellowship Medical Retina

**Licensure**

**Italy**

Unrestricted license to practice medicine and surgery (2001), and ophthalmology (2004)

GCP 16 July 2020

**Awards**

Prize winner ARVO Travel Grant Fondazione GB Bietti per lo studio e la ricerca in Oftalmologia, 2003

Prize winner clinical research “Associazione Amici di Vanda” Givre Meeting, 2009.

Prize winner “Conto Capitale” Italian Ministry of Health "Multimodal morpho-functional wide-field analysis for the neurovascular evaluation of high social impact neuro-retinal pathologies", 2015

Prize winner “LAZIOINNOVA” VALIDAZIONE DI UN NUOVO ANTICORPO MONOCLONALE MULTI-TARGETED PER IL TRATTAMENTO DI TUMORI E PATOLOGIE RETINICHE POLITERMAB. Apr 2021

### **Professional Memberships**

Author and reviewer for systematic revision for Cochrane Eyes and Vision from 2009 al 2020

EVICR.net Diabetic Retinopathy and Vascular Diseases Expert Committee 2017-today

Association for Research in Vision and Ophthalmology (ARVO)

Club Jules Gonin

Macula Society

American Academy of Ophthalmology (2008-2010)

European Retinal Specialists Society (EURETINA)

Italian Retina Society (SIR)- Steering Committee 2015-today

Società Italiana di Oftalmologia (SOI)

### **Principal Investigator (PI) / Co-Investigator in clinical trials (CoI) –**

#### **(selected list)**

##### **Co-Investigator in the multicentric studies**

- A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open label extension) to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with macular edema following central retinal vein occlusion or branch vein occlusion. (GENEVA)
- A 3 year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior Segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with diabetic macular edema. (MEAD)
- A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
- A 12 Months Case Series open study to assess the safety and efficacy of intravitreal injection of Lucentis(Ranibizumab 0.5 mg) used in combination with Visudyne (Verteporfin PDT) in naive subjects with subfoveal CNV secondary to AMD.
- A randomized, double masked , active controlled phase 3 study of the efficacy, safety and tolerability of repeated doses of intravitreal VEGF trap-Eye in subjects with neovascular age-related macular degeneration (AMD) (VIEW2).
- A phase II prospective , randomised , multicentric diabetic macular edema dose ranging, comparison study evaluating the efficacy and safety of PF- 04523655 versus laser therapy (DEGAS).

- A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO) (GALILEO).
- Macular edema Incidence/Severity Reduction with NEVANAC<sup>®</sup>. Phase IIIb, prospective, multicenter, double-masked, randomized, parallel group, placebo controlled study.
- Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema (RETAIN).
- Multicentric, phase 3, randomized, double blind, active control, 12 months follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab vs photodynamic therapy in myopic CNV.
- A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema (VIVID).
- A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex<sup>®</sup> Versus Lucentis<sup>®</sup> in Patients with Branch Retinal Vein Occlusion (COMO).
- A multicenter, open-label, randomized study comparing the efficacy and safety of 700 µg Dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema.
- A non-interventional study in patients with diabetic macula edema (DME) with central involvement to assess the effectiveness of existing anti vascular endothelial growth factor (anti-VEGF) treatment regimens (POLARIS).
- Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) *versus* PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS).
- A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) (MINERVA). Novartis.
- A 12 months, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Novartis.
- A 12-month, phase IIIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration (TREND). Novartis.
- A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista<sup>™</sup> (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis<sup>®</sup> compared to Lucentis<sup>®</sup> monotherapy in subjects with subfoveal neovascular age-related macular degeneration (FOVISTA). Ophthotec.

## Curriculum Vitae

- A Collaborative Retrospective Trial on the Efficacy and Safety of intravitreal dexamethasone implant (Ozurdex) in patients with Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES). Allergan.
- A multicenter, single-arm, interventional Phase 4 study to evaluate a treat and extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion (CENTERA)
- Managing neovascular age related macular degeneration over 2 years with a treat and extend regimen of 2 mg intravitreal aflibercept-a randomized, open label, active controlled, parallel group phase IV/IIIb study (ARIES)
- An open label, randomized, active controlled, parallel group, phase 3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age related macular degeneration (AZURE)
- An observational study program to investigate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting (AURIGA)
- Evidence of Anti-VEGF use in real Life Experience-a A retrospective cohort study from secondary data source in Italy- chart Review (EAGLE)
- A randomized,double-masked,placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 weeks with a 12 weeks follow up period in patients with Non-Proliferative diabetic retinopathy without center-involved diabetic macular edema (ROBIN study)
- A two-year, three-arm, randomized, double-masked,multicenter,phaseIII study assessing the efficacy and safety of Brolocizumab versus aflibercept in adult patients with visual impairment due to Diabetic Macular Edema (KESTREL) NOVARTIS
- An eighteen-month, two-arm,randomized,double-masked,multicenter,phase III study assessing the efficacy and safety of Brolocizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (RAPTOR) NOVARTIS
- A Phase III, Multi-Center, Randomized, Double-Masked, ShamControlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (OAKS) APELLIS
- A phase 3 multicenter, randomized, double-masked, sham-controlled clinical trial to asses the safety and efficacy of intravitreal administration of Zimura (complement CS inhibitor) in patients with geographic atrophy secondary to dry age-related macular degeneration. (ISEE2008) IVERIC-BIO

**Principal Investigator in the multicentric studies**

- Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration (DARPin) (SEQUOIA). Allergan
- A phase III, multicenter, randomized, double-masked, sham-controlled study of efficacy and safety of

- 10 mg lampalizumab intravitreal injections administered every 30 or 45 days to patients with Geographic atrophy secondary to age related macular degeneration. (CHROMA) ROCHE
- Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD)- (MACUSTAR) EVICR.net
  - A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema (YOSEMITE) ROCHE
  - A multicenter, double-masked, randomized, dose-ranging Trial to evaluate the efficacy and safety of Conbercept intravitreal injection in subjects with Neovascular age-Related Macular degeneration (PANDA) Chengdu Kanghong Pharmaceutical Industry Group Co., Ltd.
  - A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age related macular degeneration (TENAYA) ROCHE
  - Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia - RECOGNISED Sponsor: Fundació Hospital Universitari Vall D'Hebron, VHIR. Horizon 2020
  - One Year, single arm, open label, multicenter, phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolution in wAMD patients treated with brolocizumab-IMAGINE study. Novartis
  - A phase 2, randomized, multicenter study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular edema (DME). (KALAHARI) OXURION
  - A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic macular edema (RHONE-X) ROCHE
  - A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with neovascular age related macular degeneration (AVONELLE-X) ROCHE
  - A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central or hemiretinal vein occlusion. (COMINO) ROCHE
  - Patient experience and preference (PEP) study in nAMD and DME (PEP) ROCHE
  - Characterization of retinal disease progression in eyes with NPDR in diabetes Type 2 using non-invasive procedures (CHART) AIBILI
- Data and Safety Monitoring Board Clinical Trials Member**
- PROTOCOL FYB201-C2015-01-P3 (EudraCT nr: 2015-001961-20): EFFICACY AND SAFETY OF THE BIOSIMILAR RANIBIZUMAB FYB201 IN COMPARISON TO LUCENTIS IN PATIENTS

WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (COLUMBUS-AMD).  
SPONSOR BIOEQ.GmbH. 2016-2018

- A PHASE 3 RANDOMIZED, DOUBLE MASKED, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF THE PROPOSED AFLIBERCEPT FYB203 BIOSIMILAR IN COMPARISON TO EYLEA® IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION (MAGELLAN AMD). EudraCT No 2019-003923-39. SPONSOR BIOEQ.GmbH. Ongoing

### **Editor in Chief, Associate Editor, Editorial Board Member for International Peer Reviewed Journal**

- Expert Review of Ophthalmology
- Italian Review of Ophthalmology

### **Scientific Reviewer for International Peer Reviewed Journal –**

#### **(selected list)**

Acta Ophthalmologica  
Acta Diabetologica  
American Journal of Ophthalmology  
British Journal of Ophthalmology  
Clinical Ophthalmology  
European Journal of Ophthalmology  
IOVS  
JAMA ophthalmology  
Journal of Ocular Pharmacology and Therapeutics  
Ophthalmic Research  
Ophthalmologica  
Ophthalmology  
PLOS one  
Retina  
Retinal Cases & Brief Reports

### **Publications**

*Journal Articles (sort by publication date):*

**PUBMED link:** <https://www.ncbi.nlm.nih.gov/pubmed/?term=parravano+m>

1. Manni G, Centofanti M, Sacchetti M, Oddone F, Bonini S, **Parravano M**, Bucci MG. Demographic and clinical factors associated with the development of Brimonidine tartrate 0.2% induced ocular allergy. *J Glaucoma*, April 2004,13(2):163-7.
2. Manni G, Centofanti M, **Parravano M**, Oddone F, Bucci MG. A six month randomized clinical trial comparing Bimatoprost 0.03% versus the association of Timolol 0.5% and Latanoprost 0.005% in glaucomatous patients.. *Graefe's Archive for Clinical and Experimental Ophthalmology* 2004; 242: 767-770.
3. Manni G, Centofanti M, Oddone F, **Parravano M**, Bucci MG. Interleukin-1  $\beta$  tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free non selective beta-blockers. *Am J Ophthalmol* 2005; 139: 72-77.
4. Centofanti M, Oddone F, **Parravano M**, Gualdi L, Manni G. Corneal birefringence changes after laser assisted in situ keratomileusis and their influence on retinal nerve fibre layer thickness measurement by means of scanning laser polarimetry.. *Br J Ophthalmol* 2005 Jun;89(6):689-93.
5. Bucci MG, **Parravano M**, Balacco Gabrieli C, Pecori-Giraldi J, Librando A, Paone E, Bores LD Pilot study to evaluate the efficacy and safety of pneumatic trabeculoplasty in glaucoma and ocular hypertension. *Eur J Ophthalmol*. 2005;15(3):347-52
6. **Parravano M**, Oddone F, Sampalmieri M, Gazzaniga D. Reliability of the IOLMaster in axial length evaluation in silicone oil-filled eyes. *Eye* 2007;21 (7): 909-911, 2006 Jul 28; [Epub ahead of print]
7. Ricci F, Missiroli F, **Parravano M**. Argon Laser Trabeculoplasty in Triamcinolone Acetonide induced ocular hypertension refractory to maximal medical treatment. *Eur J Ophthalmol*. 2006 Sep-Oct;16(5):756-7.
8. Orzalesi N, Rossetti L on behalf of the OPTIME Study Group (Osservatorio sulla Patologia glaucomatosa, Indagine Medico Epidemiologica), CONPROSO (Collegio Nazionale dei Professori Ordinari di Scienze Oftalmologiche). Vascular risk factors in glaucoma: the results of a national survey. *Graefes Arch Clin Exp Ophthalmol*. 2007 Jun;245(6):795-802
9. Ferranini M, Vischini G, Staffolani E, Scaccia F, Miani N, **Parravano MC**, Louis MM, Splendiani G, Di Daniele N. Rheopheresis in vascular diseases. *Int J Artif Organs* 2007; 30(10):923-9
10. **Parravano M**, Oddone F, Mineo D, Centofanti M, Borboni P, Lauro R, Tanga L, Manni G. The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. *Br J Ophthalmol*. 2008 Dec; 92(12):1656-60. Epub 2008 Oct 1.
11. Schiano Lomoriello D, **Parravano MC**, Chiaravalloti A, Varano M. Choroidal neovascularization in angioid streaks and pseudoxanthoma elasticum: 1 year follow-up. *Eur J Ophthalmol*. 2009 Jan-Feb;19(1):151-3.
12. **Parravano M**, Oddone F, Tedeschi M, Lomoriello DS, Chiaravalloti A, Ripandelli G, Varano M.

- Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. *Retina*. 2009 Mar; 29(3):329-34
13. Varano M, Tedeschi M, Oddone F, Perillo L, Coppè AM, **Parravano M**. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal Ranibizumab. *Retina*. 2010 Mar;30(3):413-7.
  14. **Parravano M**, Oddone F, Tedeschi M, Lomoriello DS, Chiaravalloti A, Ripandelli G, Varano M. Microperimetry in neovascular age-related macular degeneration (AMD). Letter to the Editor. *Retina* 2009 29(10): 1549-50.
  15. **Parravano M**, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. *Cochrane Database of Systematic Reviews* 2009, Issue 4.
  16. **Parravano M**, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, Varano M. "Retinal functional changes measured by microperimetry in neovascular age related macular degeneration treated with ranibizumab: 24 months results". *Retina*. 2010 Jul-Aug;30(7):1017-24.
  17. **Parravano M**, Oddone F, Boccassini B, Menchini F, Chiaravalloti A, Schiavone M, Varano M. Reproducibility of Macular Thickness Measurements Using Cirrus Spectral Domain Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2010 Sep;51(9):4788-91. Epub 2010 Apr 30.
  18. Piemarocchi S, Varano M, **Parravano M**, Oddone F, Sartore M, Ferrara R, Sera F and Virgili G. Quality of Vision Index (QOVI): A New Method to Appraise Visual Function Changes in Age-related Macular Degeneration. *Eur J Ophthalmol*. 2011 Jan-Feb;21(1):55-66.
  19. Tanga L, Centofanti M, Oddone F, **Parravano M**, Parisi V, Ziccardi L, Kroegler B, Perricone R, Manni G. Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine. *Graefes Arch Clin Exp Ophthalmol*. 2011 May;249(5):715-21. Epub 2011 Jan 21.
  20. Oddone F, Centofanti M, Tanga L, **Parravano M**, Michelessi M, Schiavone M, Villani CM, Fogagnolo P, Manni G. Influence of Disc Size on Optic Nerve Head versus Retinal Nerve Fiber Layer Assessment for Diagnosing Glaucoma. *Ophthalmology*. 2011 Jul;118(7):1340-7. Epub 2011 Apr 7.
  21. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology*. 2011 Dec;118(12):2453-60. Epub 2011 Jul 20.
  22. **Parravano M**, Pilotto E, Musicco I, Varano M, Introini U, Staurenghi G, Menchini U, Virgili G. Reproducibility of fluorescein and indocyanine green angiographic assessment for RAP diagnosis: a multicenter study. *Eur J Ophthalmol*. 2011 Nov 28:0. doi: 10.5301/ejo.5000087. [Epub ahead of print]
  23. **Parravano M**, Sciamanna M, Giorno P, Boninfante A, Varano M. Bietti crystalline dystrophy: a morpho-functional evaluation. *Doc Ophthalmol*. 2012 Feb;124(1):73-7. Epub 2011 Dec 29.
  24. Reibaldi M, **Parravano M**, Varano M, Longo A, Avitabile T, Uva MG, Zagari M, Toro M, Boscia F, Boccassini B, Chiaravalloti A, Mariotti C, Reibaldi A. Foveal Microstructure and

- Functional Parameters in Lamellar Macular Hole. *Am J Ophthalmol*. 2012 Sep 8. [Epub ahead of print]
25. Cacciamani A, Oddone F, **Parravano M**, Scarinci F, Di Nicola M, Lofoco G. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. *Jpn J Ophthalmol*. 2012 Oct 24. [Epub ahead of print]
  26. Virgili G, **Parravano M**, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. *Cochrane Database Syst Rev*. 2012 Dec 12;12:CD007419.doi:10.1002/14651858.CD007419.pub3.
  27. **Parravano M**, Oddone F, Boccassini B, Chiaravalloti A, Scarinci F, Sciamanna M, Boninfante A, Tedeschi M, Varano M. Functional and structural assessment of lamellar macular holes. *Br J Ophthalmol*. 2012 Dec 19. [Epub ahead of print]
  28. Lombardo M, Serrao S, Devaney N, **Parravano M**, Lombardo G. Adaptive optics technology for high-resolution retinal imaging. *Sensors (Basel)*. 2012 Dec 27;13(1):334-66.doi: 10.3390/s130100334. PMID: 23271600 [PubMed - in process]
  29. **Parravano M**, Oddone F, Boccassini B, Centofanti M, Tanga L, Cacciamani A, Borboni P, Varano M. Functional retinal impairment in type 1 diabetic patients without any signs of retinopathy. *Ophthalmic Res*. 2013 Jul 3;50(2):108-112. [Epub ahead of print]
  30. Lombardo M, **Parravano M**, Serrao S, Ducoli P, Stirpe M, Lombardo G. Analysis of retinal capillaries in patients with type 1 diabetes and non proliferative diabetic retinopathy using adaptive optics imaging. *Retina*. 2013 Sep;33(8):1630-9
  31. Lombardo M, **Parravano M**, Lombardo G, Varano M, Boccassini B, Stirpe M, Serrao S. Adaptive optics imaging of parafoveal cones in type 1 diabetes. *Retina* 2014;34(3):546-57.
  32. Varano M, Boninfante A, Ziccardi L, Oddone F, Giorno P, Lioi S, Valli Fiore V, De Geronimo D, Parisi V, **Parravano M**. Modificazioni retiniche morfo-funzionali a lungo termine nella degenerazione maculare di tipo secco in terapia con supplementazione orale a base di Luteina, Zeaxantina, DHA microalgale, Tocotrienoli, Vitamine e minerali." *Ottica Fisiopatologica* Marzo 2013
  33. Virgili G, **Parravano M**, Menchini F, Brunetti M. Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations? *Br J Ophthalmol*. 2014 Apr;98(4):421-2.
  34. **Parravano M**, Parisi V, Ziccardi L, Chiaravalloti A, Tedeschi M, Cacciamani A, Boccassini B, Boninfante A, Varano M. Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment. *Doc Ophthalmol*. 2013 Dec;127(3):217-25
  35. Lazzeri S, Piaggi P, **Parravano M**, et al. Analysis of Functional Dissociations between Best Corrected Visual Acuity and Microperimetric Parameters in Neovascular Age-Related Macular Degeneration Patients Underwent to Three Monthly Ranibizumab Injections. *J Clin Exp Ophthalmol* in press
  36. Coscas G, Augustin A, Bandello F, de Smet M, Lanzetta P, Staurenghi G, **Parravano M**, Udaondo P, Moisseiev E, Soubrane G, Yatziv Y, Loewenstein A. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. *Eur J Ophthalmol*. 2014 Jan-Feb;24(1):1-9.

37. **Parravano M**, Oddone F, Boccassini B, Giorno P, Chiaravalloti A, Tedeschi M, Scarinci F, Varano M. Exploring the morphological and functional retinal changes after Dexamethasone Intravitreal Implant (Ozurdex®) in macular edema due to retinal vein occlusion. *Ophthalmic Res.* 2014;51(3):153-60. doi: 10.1159/000357275. Epub 2014 Mar 13.
38. Varano M, Iacono P, Giorno P, Chiaravalloti A, **Parravano M**. Photodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: 10 years retrospective analysis. *Ophthalmologica.* 2014;231(4):204-10
39. **Parravano M**, Ricci F, Oddone F, Missiroli F, De Felici C, Varano M. Long term functional and morphological retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization. *Retina.* 2014 Oct;34(10):2053-62
40. **Parravano M**, Oddone F, Giorno P, Cacciamani A, Abbate R, Caminiti G, Peiretti E, Varano M. Influence of macular choroidal thickness on visual function in highly myopic eyes. *Ophthalmic Res.* 2014;52(2):97-101.
41. Matteucci A, Gaddini L, Villa M, Varano M, **Parravano M**, Monteleone V, Cavallo F, Leo L, Mallozzi C, Malchiodi-Albedi F, Pricci F. Neuroprotection by rat Müller glia against high glucose-induced neurodegeneration through a mechanism involving ERK1/2 activation. *Exp Eye Res.* 2014 Aug;125:20-9
42. Cacciamani A, Scarinci F, **Parravano M**, Giorno P, Varano M. Choroidal thickness changes with photodynamic therapy for a diffuse choroidal hemangioma in Sturge-Weber syndrome. *Int Ophthalmol.* 2014 Mar 23. [Epub ahead of print]
43. Lazzeri S, Figus M, Sartini MS, Scarinci F, Casini G, Guidi G, Cupo G, Cacciamani A, Fasanella V, Agnifili L, Piaggi P, Varano M, Ripandelli G, Nardi M, **Parravano M**. Intravitreal ranibizumab for predominantly haemorrhagic choroidal neovascularization in age related macular degeneration. *Ophthalmologica.* 2015;233(2):74-81
44. Bandello F, **Parravano M**, Cavallero E, Cascavilla ML, Triolo G, Querques L, Borrelli E, Giorno P, Varano M, Lattanzio R, Querques G. Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. *Ophthalmic Res.* 2015;53(4):207-16.
45. Virgili G, **Parravano M**, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. *Cochrane Database Syst Rev.* 2014 Oct 24;10:CD007419. [Epub ahead of print]
46. **Parravano M**, Giansanti F, Eandi CM, Yap YC, Rizzo S, Virgili G. Vitrectomy for idiopathic macular hole. *Cochrane Database Syst Rev.* 2015 May 12;5:CD009080.
47. Parodi Battaglia M, Iacono P, Petruzzi G, **Parravano M**, Varano M, Bandello F. Dexamethasone Implant for Macular Edema Secondary to Ischemic Retinal Vein Occlusions. *Retina.* 2015 Jul;35(7):1387-92
48. Maurizio B.Parodi, Pierluigi Iacono, Giuseppe Petruzzi, **Mariacristina Parravano**, Monica Varano, Francesco Bandello. Dexamethasone Implant for Macular Edema Secondary to Central Retinal Vein Occlusion in patients aged under 50 years. *Retina.* 2015 Jul;35(7):1381-6.
49. Stefano Lazzeri, Guido Ripandelli, Maria Sole Sartini, **Mariacristina Parravano**, Monica Varano, Marco Nardi, Teresa Di Desidero, Paola Orlandi, Guido Bocci. Aflibercept

- administration in neovascular age related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. *Angiogenesis* 2015 Oct;18(4):397-432
50. Valentina Sarao, **Mariacristina Parravano**, Daniele Veritti, Luis Arias, Monica Varano, Paolo Lanzetta. Intravitreal Aflibercept for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Ranibizumab Therapy. *Retina*. 2016 Apr;36(4):770-7.
  51. Cacciamani A, **Parravano M**, Scarinci F, Esposito G, Varano M, Micera A. A Simple Spontaneous Vitreal Reflux Collecting Procedure During Intravitreal Injection: Set-Up and Validation Studies. *Curr Eye Res*. 2015 Oct 15:1-6. [Epub ahead of print]
  52. Ribeiro L, Bandello F, Tejerina AN, Vujosevic S, Varano M, Egan C, Sivaprasad S, Menon G, Massin P, Verbraak FD, Lund-Andersen H, Martinez JP, Jürgens I, Smets E, Coriat C, Wiedemann P, Ágoas V, Querques G, Holz FG, Nunes S, Neves C, Cunha-Vaz J; Evicr Net Study Group. Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2. *Invest Ophthalmol Vis Sci*. 2015 Aug;56(9):5698-705.
  53. Manuele Michelessi, Ersilia Lucenteforte, Francesco Oddone, Miriam Brazzelli, **Mariacristina Parravano**, Sara Franchi, Sueko M Ng, Gianni Virgili. Optic nerve head and fibre layer imaging for diagnosing glaucoma. *Cochrane Database Syst Rev*. Online 30 Nov 2015.
  54. Lazzeri S, Orlandi P, Piaggi P, Sartini MS, Casini G, Guidi G, Figus M, Fioravanti A, Di Desidero T, Ripandelli G, **Parravano M**, Varano M, Nardi M, Bocci G. IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. *Pharmacogenomics*. 2016;17(1):35-9. doi: 10.2217/pgs.15.153. Epub 2015 Dec 14.
  55. **Parravano M**, Querques L, Boninfante A, Giorno P, Varano M, Bandello F, Querques G. Reticular pseudodrusen characterization by retromode imaging. *Acta Ophthalmol*. 2016 Jan 27. doi: 10.1111/aos.12948. [Epub ahead of print] No abstract available.
  56. Oddone F, Lucenteforte E, Michelessi M, Rizzo S, Donati S, **Parravano M**, Virgili G. Macular versus Retinal Nerve Fiber Layer Parameters for Diagnosing Manifest Glaucoma: A Systematic Review of Diagnostic Accuracy Studies. *Ophthalmology*. 2016 Feb 15. pii: S0161-6420(16)00002-6. doi: 10.1016/j.optha.2015.12.041. [Epub ahead of print]
  57. Lombardo M, **Parravano M**, Serrao S, Ziccardi L, Giannini D, Lombardo G. Investigation of Adaptive Optics Imaging Biomarkers for Detecting Pathological Changes of the Cone Mosaic in Patients with Type 1 Diabetes Mellitus. *PLoS One*. 2016 Mar 10;11(3):e0151380. doi: 10.1371/journal.pone.0151380. eCollection 2016.
  58. Virgili G, **Parravano M**, Schmucker C. Managing Neovascular Age-Related Macular Degeneration: Is More Research Needed to Improve Real-world Practice? *JAMA Ophthalmol*. 2016 Mar 24. doi: 10.1001/jamaophthalmol.2016.0332. [Epub ahead of print] No abstract available.
  59. Cacciamani A, Lazzeri S, Rossi T, Scarinci F, **Parravano M**, Ripandelli G, Pileri MA, Nardi M, Stirpe M. ADJUSTABLE MACULAR BUCKLING FOR FULL-THICKNESS MACULAR HOLE WITH FOVEOSCHISIS IN HIGHLY MYOPIC EYES: Long-Term Anatomical and Functional Results. *Retina*. 2016 Apr;36(4):709-16. doi: 10.1097/IAE.0000000000000802.
  60. Ricci F, **Parravano M**, Regine F, Sciamanna M, Tedeschi M, Missiroli F, Varano M. Aflibercept

- in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. *Eye (Lond)*. 2016 May 27. doi: 10.1038/eye.2016.95. [Epub ahead of print]
61. **Parravano M**, Querques L, Scarinci F, Giorno P, De Geronimo D, Gattegna R, Varano M, Bandello F, Querques G. Optical coherence tomography angiography in treated type 2 neovascularization undergoing monthly anti-VEGF treatment. *Acta Ophthalmol*. 2016 Aug 6. doi: 10.1111/aos.13180. [Epub ahead of print] No abstract available.
  62. Ricci F, **Parravano M**, Regine F, Sciamanna M, Tedeschi M, Missiroli F, Varano M. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. *Eye (Lond)*. 2017 Jan;31(1):163-164. doi: 10.1038/eye.2016.215. Epub 2016 Oct 7. No abstract available.
  63. Iacono Pierluigi, Battaglia Parodi Maurizio, Federico Selvi, **Mariacristina Parravano**, Chiaravalloti Adele, Varano Monica, Bandello Francesco. Factors influencing visual acuity in patients receiving anti-VEGF for myopic choroidal neovascularization. *Retina*. 2016 Dec 28. doi: 10.1097/IAE.0000000000001436. [Epub ahead of print]
  64. Veritti D, Sarao V, **Parravano M**, Arias L, Varano M, Lanzetta P. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study. *Eur J Ophthalmol*. 2017 Jan 19;27(1):74-79. doi: 10.5301/ejo.5000880. Epub 2016 Oct 27.
  65. Longo A, Casuccio A, Pani L, Avitabile T, Cillino S, Uva MG, Bonfiglio V, Russo A, Parisi G, Cennamo G, Furino C, **Parravano M**, Xoxi E, Reibaldi M. Association of neovascular age-related macular degeneration with month and season of birth in Italy. *Aging (Albany NY)*. 2016 Dec 19;9(1):133-141. doi: 10.18632/aging.101137.
  66. Scarinci F, Picconi F, Virgili G, Giorno P, Di Renzo A, Varano M, Frontoni S, **Parravano M**. Single retinal layer evaluation in patients with type 1 diabetes with no or early signs of diabetic retinopathy: the first hint of neurovascular crosstalk damage between neurons and capillaries? *Ophthalmologica*. 2017 Apr 8. doi: 10.1159/000453551
  67. Joseph M. Simonett, MD, Fabio Scarinci, MD, Fabiana Picconi, MD, Paola Giorno, MD, Daniele De Geronimo, MD, Antonio Di Renzo, PhD, Monica Varano, MD, Simona Frontoni, MD, PhD, **Mariacristina Parravano**, MD Early microvascular retinal changes on Optical Coherence Tomography Angiography in patients with Type 1 Diabetes Mellitus. *Acta Ophthalmol*. 2017 Feb 16. doi: 10.1111/aos.13404. [Epub ahead of print]
  68. Fabiana Picconi, **Mariacristina Parravano**, Dorina Ylli, Patrizio Pasqualetti, Sara Coluzzi, Ilaria Giordani, Ilaria Malandrucco, Davide Lauro, Fabio Scarinci, Paola Giorno, Monica Varano, Simona Frontoni. Early retinal neurodegeneration in patients with type 1 diabetes mellitus: the role of glycemic variability. *Acta Diabetol*. 2017 May;54(5):489-497. doi: 10.1007/s00592-017-0971-4. Epub 2017 Feb 25.
  69. **Parravano M**, De Geronimo D, Scarinci F, Querques L, Virgili G, Simonett JM, Varano M, Bandello F, Querques G. Relationship between internal reflectivity of diabetic microaneurysms on SD-OCT and detection on OCT Angiography. *Am J Ophthalmol*. 2017 May 5. pii: S0002-9394(17)30190-3. doi: 10.1016/j.ajo.2017.04.021. [Epub ahead of print]
  70. Querques L, **Parravano M**, Sacconi R, Rabiolo A, Bandello F, Querques G. Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study. *Acta Diabetol*. 2017 Jun 2. doi: 10.1007/s00592-017-1010-1. [Epub ahead of print]

71. Varano M, Iacono P, Tedeschi MM, Letizia C, Curione M, Savoriti C, Baiocco E, Zinamosca L, Marinelli C, Boccassini B, **Parravano M**. Comparisons of microvascular and macrovascular changes in aldosteronism-related hypertension and essential hypertension. *Sci Rep*. 2017 Jun 1;7(1):2666. doi: 10.1038/s41598-017-02622-2.
72. Pilotto E, Guidolin F, **Parravano M**, Viola F, De Geronimo D, Convento E, dell'Arti L, Tabacchi E, Parozzani R, Cavarzeran F, Midena E. MORPHOFUNCTIONAL EVALUATION IN DOME-SHAPED MACULA: A MICROPERIMETRY AND OPTICAL COHERENCE TOMOGRAPHY STUDY. *Retina*. 2017 May 22. doi: 10.1097/IAE.0000000000001621. [Epub ahead of print]
73. Villa M, **Parravano M**, Micheli A, Gaddini L, Matteucci A, Mallozzi C, Facchiano F, Malchiodi-Albedi F, Pricci F. A quick, simple method for detecting circulating fluorescent advanced glycation end-products: Correlation with in vitro and in vivo non-enzymatic glycation. *Metabolism*. 2017 Jun;71:64-69. doi: 10.1016/j.metabol.2017.03.004. Epub 2017 Mar 9.
74. Rabiolo A, **Parravano M**, Querques L, Cicinelli MV, Carnevali A, Sacconi R, Centoducati T, Vujosevic S, Bandello F, Querques G. Ultra-wide-field fluorescein angiography in diabetic retinopathy: a narrative review. *Clin Ophthalmol*. 2017 Apr 27;11:803-807. doi: 10.2147/OPHTH.S133637. eCollection 2017. Review.
75. Marchese A, **Parravano M**, Rabiolo A, Carnevali A, Corbelli E, Cicinelli MV, Battaglia Parodi M, Querques L, Bandello F, Querques G. Optical coherence tomography analysis of evolution of Bruch's membrane features in angioid streaks. *Eye (Lond)*. 2017 Jun 16. doi: 10.1038/eye.2017.112. [Epub ahead of print]
76. Virgili G, **Parravano M**, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. *Cochrane Database Syst Rev*. 2017 Jun 22;6:CD007419. doi:10.1002/14651858.CD007419.pub5. Review. PubMed PMID: 28639415.
77. Eandi CM, Ciardella A, **Parravano M**, Missiroli F, Alovisi C, Veronese C, Morara MC, Grossi M, Virgili G, Ricci F. Indocyanine Green Angiography and Optical Coherence Tomography Angiography of Choroidal Neovascularization in Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2017 Jul 1;58(9):3690-3696. doi:10.1167/iovs.17-21941. PubMed PMID: 28738134.
78. Scarinci F, Picconi F, Giorno P, Boccassini B, De Geronimo D, Varano M, Frontoni S, **Parravano M**. Deep capillary plexus impairment in patients Type 1 Diabetes Mellitus with no signs of diabetic retinopathy revealed using optical coherence tomography angiography. *Acta Ophthalmol*. 2017 Sep 9. doi: 10.1111/aos.13510. [Epub ahead of print] No abstract available
79. **Parravano M**, Scarinci F, Gilardi M, Querques L, Varano M, Oddone F, Bandello F, Querques G. Patchy Chororetinal Atrophy Changes at the Posterior Pole After Ranibizumab for Myopic Choroidal Neovascularization. *Invest Ophthalmol Vis Sci*. 2017 Dec 1;58(14):6358-6364. doi: 10.1167/iovs.17-22633. PubMed PMID: 29260192.
80. Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, **Parravano M**. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. *Retina*. 2018 Jan 16. doi: 10.1097/IAE.0000000000002040. [Epub ahead of print] PubMed PMID: 29346241
81. Mallozzi C, **Parravano M**, Gaddini L, Villa M, Pricci F, Malchiodi-Albedi F, Matteucci A. Curcumin Modulates the NMDA Receptor Subunit Composition Through a Mechanism

- Involving CaMKII and Ser/Thr Protein Phosphatases. *Cell Mol Neurobiol*. 2018 May 30. doi: 10.1007/s10571-018-0595-4. [Epub ahead of print] PubMed PMID: 29846839.
82. Giovannini A, **Parravano M**, Ricci F, Bandello F. Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach. *Eur J Ophthalmol*. 2018 Jun 1:1120672118781236. doi: 10.1177/1120672118781236. [Epub ahead of print] PubMed PMID: 29882421.
  83. Virgili G, Evans J, **Parravano M**. Prioritizing Questions and Outcomes for Guidelines on Age-Related Macular Degeneration: Moving Beyond the Clinical Encounter. *JAMA Ophthalmol*. 2018 Aug 16. doi: 10.1001/jamaophthalmol.2018.3455. [Epub ahead of print] PubMed PMID: 301285.
  84. Ziccardi L, Parisi V, Picconi F, Di Renzo A, Lombardo M, Frontoni S, **Parravano M**. Early and localized retinal dysfunction in patients with type 1 diabetes mellitus studied by multifocal electroretinogram. *Acta Diabetol*. 2018 Aug 28. doi: 10.1007/s00592-018-1209-9. [Epub ahead of print] PubMed PMID: 30159747.
  85. **Parravano M**, De Geronimo D, Scarinci F, Virgili G, Querques L, Varano M, Bandello F, Querques G. Progression of diabetic microaneurysms according to the internal reflectivity on structural OCT and visibility on OCT angiography. *Am J Ophthalmol*. 2018 Oct 8. pii: S0002-9394(18)30573-7. doi: 10.1016/j.ajo.2018.09.031. [Epub ahead of print] PubMed PMID: 30308201
  86. Bellanca RF, Scarinci F, **Parravano M**. Multimodal imaging in a young male with osteogenesis imperfecta complicated with choroidal neovascularization. *Eur J Ophthalmol*. 2018 Nov 8:1120672118811247. doi: 10.1177/1120672118811247. [Epub ahead of print] PubMed PMID: 30409043.
  87. Pepe J, Cipriani C, Tedeschi M, Curione M, **Parravano M**, Varano M, Biamonte F, Colangelo L, Minisola S. Retinal micro-vascular and aortic macro-vascular changes in postmenopausal women with primary hyperparathyroidism. *Sci Rep*. 2018 Nov 8;8(1):16521. doi: 10.1038/s41598-018-35017-y. PubMed PMID: 30410012; PubMed Central PMCID: PMC6224616.
  88. Picconi F, Mataluni G, Ziccardi L, **Parravano M**, Di Renzo A, Ylli D, Pasqualetti P, Studer V, Chioma L, Marfia GA, Frontoni S. Association between Early Neuroretinal Dysfunction and Peripheral Motor Unit Loss in Patients with Type 1 Diabetes Mellitus. *J Diabetes Res*. 2018 Oct 4;2018:9763507. Doi 10.1155/2018/9763507. eCollection 2018. PubMed PMID: 30402503; PubMed Central PMCID: PMC6193343.
  89. Cacciamani A, Esposito G, Scarinci F, **Parravano M**, Dinice L, Di Nicola M, Micera A. Inflammatory mediators in the vitreal reflux of patients with diabetic macular edema. *Graefes Arch Clin Exp Ophthalmol*. 2018 Oct 30. doi: 10.1007/s00417-018-4169-4. [Epub ahead of print] PubMed PMID: 30377797.
  90. Scarinci F, Ghiciuc CM, Patacchioli FR, Palmery M, **Parravano M**. Investigating the Hypothesis of Stress System Dysregulation as a Risk Factor for Central Serous Chorioretinopathy: A Literature Mini-Review. *Curr Eye Res*. 2019 Jan 9:1-7. doi: 10.1080/02713683.2019.1565891. [Epub ahead of print] PubMed PMID: 30624085.
  91. Iacono P, Toto L, Eliana C, Varano M, **Parravano MC**. Pharmacotherapy of central serous chorioretinopathy: review of the current treatments. *Curr Pharm Des*. 2019 Jan 23. doi: 10.2174/1381612825666190123165914. [Epub ahead of print] PubMed PMID: 30674250.

92. Costanzo E, **Parravano M**, Gilardi M, Cavalleri M, Sacconi R, Aragona E, Varano M, Bandello F, Querques G. Microvascular Retinal and Choroidal Changes in Retinal Vein Occlusion Analyzed by Two Different Optical Coherence Tomography Angiography Devices. *Ophthalmologica*. 2019 Feb 5:1-8. doi: 10.1159/000496195. [Epub ahead of print] PubMed PMID: 30721901.
93. Sciarretta F, Fulci C, Palumbo C, Aquilano K, Pastore A, Iorio E, Lettieri-Barbato D, Cicconi R, Minutolo A, **Parravano M**, Gilardi M, Varano M, Caccuri AM. Glutathione transferase P silencing promotes neuronal differentiation of retinal R28 cells. *J Cell Physiol*. 2019 Feb 11. doi: 10.1002/jcp.28246. [Epub ahead of print] PubMed PMID: 30741416.
94. Panozzo G, Staurenghi G, Dalla Mura G, Giannarelli D, Alessio G, Alongi S, Appolloni R, Baldascino A, Boscia F, Caporossi A, Cereda M, D'Ugo E, Fallico M, Avitabile T, Galan A, La Spina C, Lo Giudice G, Mastropasqua L, Palmisano C, Panico C, **Parravano MC**, Penna R, Pintore P, Vaiano A, Reibaldi M, Rizzo S, Rossi T, Varano M, Virgili G. Prevalence of diabetes and diabetic macular edema in patients undergoing senile cataract surgery in Italy: The DIabetes and CATaract study. *Eur J Ophthalmol*. 2019 Mar 11:1120672119830578. doi: 10.1177/1120672119830578. [Epub ahead of print] PubMed PMID: 30854895.
95. Corbelli E, **Parravano M**, Sacconi R, Sarraf D, Yu SY, Kim K, Capuano V, Miere A, Souied E, Varano M, Boninfante A, Chae B, Carnevali A, Querques L, Bandello F, Querques G. Prevalence and Phenotypes of Age-Related Macular Degeneration in Eyes With High Myopia. *Invest Ophthalmol Vis Sci*. 2019 Apr 1;60(5):1394-1402. doi:10.1167/iovs.18-25534. PubMed PMID: 30938774.
96. **Parravano M**, Borrelli E, Sacconi R, Costanzo E, Marchese A, Manca D, Varano M, Bandello F, Querques G. A Comparison Among Different Automatically Segmented Slabs to Assess Neovascular AMD using Swept Source OCT Angiography. *Transl Vis Sci Technol*. 2019 Mar 27;8(2):8. doi: 10.1167/tvst.8.2.8. eCollection 2019 Mar. PubMed PMID: 30941265; PubMed Central PMCID: PMC6438244.
97. Querques L, **Parravano M**, Borrelli E, Chiaravalloti A, Tedeschi M, Sacconi R, Zucchiatti I, Bandello F, Querques G. Anatomical and functional changes in neovascular AMD in remission: comparison of fibrocellular and fibrovascular phenotypes. *Br J Ophthalmol*. 2019 Apr 18. pii: bjophthalmol-2018-313685. doi: 10.1136/bjophthalmol-2018-313685. [Epub ahead of print] PubMed PMID: 31000509.
98. Virgili G, **Parravano M**, Viola F, Varano M. Vision-related quality of life in patients treated for myopic choroidal neovascularization: A post hoc analysis of the OLIMPIC study. *Eur J Ophthalmol*. 2019 Jun 6:1120672119853745. doi: 10.1177/1120672119853745. [Epub ahead of print] PubMed PMID: 31169023.
99. Picconi F, **Parravano M**, Sciarretta F, Fulci C, Nali M, Frontoni S, Varano M, Maria Caccuri A. Activation of retinal Müller cells in response to glucose variability. *Endocrine*. 2019 Jul 20. doi: 10.1007/s12020-019-02017-5. [Epub ahead of print] PubMed PMID: PMID: 31327157
100. Schiano Lomoriello D, Abicca I, **Parravano M**, Giannini D, Russo B, Frontoni S, Picconi F. Early Alterations of Corneal Subbasal Plexus in Uncomplicated Type 1 Diabetes Patients. *J Ophthalmol*. 2019 Jul 2;2019:9818217. doi: 10.1155/2019/9818217. eCollection 2019. PubMed PMID: 31341662; PubMed Central PMCID: PMC6636466.
101. Cavalleri M, Cicinelli MV, **Parravano M**, Varano M, De Geronimo D, Sacconi R, Bandello F, Querques G. Prognostic role of optical coherence tomography after switch to dexamethasone in

- diabetic macular edema. *Acta Diabetol.* 2019 Aug 2. doi: 10.1007/s00592-019-01389-4. [Epub ahead of print] PubMed PMID: 31375899.
102. Borrelli E, Zuccaro B, Zucchiatti I, **Parravano M**, Querques L, Costanzo E, Sacconi R, Prascina F, Scarinci F, Bandello F, Querques G. Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy. *J Clin Med.* 2019 Aug 22;8(9). pii: E1271. doi: 10.3390/jcm8091271. PubMed PMID: 31443376.
  103. **Parravano M**, Tedeschi M, Manca D, Costanzo E, Di Renzo A, Giorno P, Barbano L, Ziccardi L, Varano M, Parisi V. Correction to: Effects of Macuprev(®)Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up. *Adv Ther.* 2019 Nov;36(11):3288. doi: 10.1007/s12325-019-01094-2. PubMed PMID: 31538305; PubMed Central PMCID: PMC6822796.
  104. Accorinti M, Gilardi M, De Geronimo D, Iannetti L, Giannini D, **Parravano M**. Optical Coherence Tomography Angiography Findings in Active and Inactive Ocular Behçet Disease. *Ocul Immunol Inflamm.* 2019 Sep 27:1-12. doi: 10.1080/09273948.2019.1612452. [Epub ahead of print] PubMed PMID: 31560572.
  105. Iacono P, Giorno P, Varano M, **Parravano M**. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography. *Eur J Ophthalmol.* 2019 Oct 17:1120672119882333. doi: 10.1177/1120672119882333. [Epub ahead of print] PubMed PMID: 31619075.
  106. Scarinci F, Varano M, **Parravano M**. Retinal Sensitivity Loss Correlates with Deep Capillary Plexus Impairment in Diabetic Macular Ischemia. *J Ophthalmol.* 2019 Oct 13;2019:7589841. doi: 10.1155/2019/7589841. eCollection 2019. PubMed PMID: 31737359; PubMed Central PMCID: PMC6815547.
  107. Borrelli E, Costanzo E, **Parravano M**, Viggiano P, Varano M, Giorno P, Marchese A, Sacconi R, Mastropasqua L, Bandello F, Querques G. Impact of Bleaching on Photoreceptors in Different Intermediate AMD Phenotypes. *Transl Vis Sci Technol.* 2019 Nov 12;8(6):5. doi: 10.1167/tvst.8.6.5. eCollection 2019 Nov. PubMed PMID:31737429; PubMed Central PMCID: PMC6855373.
  108. Ziccardi L, Cordeddu V, Gaddini L, Matteucci A, **Parravano M**, Malchiodi-Albedi F, Varano M. Gene Therapy in Retinal Dystrophies. *Int J Mol Sci.* 2019 Nov 14;20(22). pii: E5722. doi: 10.3390/ijms20225722. Review. PubMed PMID: 31739639; PubMed Central PMCID: PMC6888000.
  109. Borrelli E, **Parravano M**, Querques L, Sacconi R, Giorno P, De Geronimo D, Bandello F, Querques G. One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study. *Acta Diabetol.* 2019 Nov 21. Doi 10.1007/s00592-019-01435-1. [Epub ahead of print] PubMed PMID: 31749052.
  110. De Geronimo D, Giorno P, Scarinci F, Boninfante A, Varano M, **Parravano M**. Treatment of Diabetic Macular Edema with Multiple Dexamethasone Intravitreal Implants: Evidence from Real-Life Experience. *Ophthalmologica.* 2019 Nov 19. doi: 10.1159/000504890. [Epub ahead of print] PubMed PMID: 31760387.

111. Iacono P, Battaglia Parodi M, **Parravano M**, Varano M. Large choroidal excavation in retinitis pigmentosa: A case report. *Eur J Ophthalmol*. 2019 Dec 4;1120672119892438. doi: 10.1177/1120672119892438. [Epub ahead of print] PubMed PMID: 31801355.
112. Iacono P, Battaglia Parodi M, Saviano S, **Parravano M**, Varano M. Large choroidal excavation in pachychoroid disease: A case report. *Eur J Ophthalmol*. 2019 Dec 4;1120672119892428. doi: 10.1177/1120672119892428. [Epub ahead of print] PubMed PMID: 31801362.
113. Giorno P, Iacono P, Scarinci F, Di Renzo A, Varano M, **Parravano M**. Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography. *Ophthalmologica*. 2019 Dec 13:1-8. doi: 10.1159/000504755. [Epub ahead of print] PubMed PMID: 31838464.
114. Scarinci F, Patacchioli FR, Palmery M, Pasquali V, Costanzo E, Ghiciuc CM, **Parravano M**. Diurnal trajectories of salivary cortisol and  $\alpha$ -amylase and psychological profiles in patients with central serous chorioretinopathy. *Chronobiol Int*. 2019 Dec 16:1-10. doi: 10.1080/07420528.2019.1702553. [Epub ahead of print] PubMed PMID: 31842621.
115. Corbelli E, Borrelli E, **Parravano M**, Sacconi R, Gilardi M, Costanzo E, Cavalleri M, Querques L, Bandello F, Querques G. Multimodal imaging characterization of peripheral drusen. *Graefes Arch Clin Exp Ophthalmol*. 2020 Jan 3. doi: 10.1007/s00417-019-04586-7. [Epub ahead of print] PubMed PMID: 31900644.
116. Battista M, Borrelli E, **Parravano M**, Gelormini F, Tedeschi M, De Geronimo D, Sacconi R, Querques L, Bandello F, Querques G. OCTA characterisation of microvascular retinal alterations in patients with central serous chorioretinopathy. *Br J Ophthalmol*. 2020 Jan 16. pii: bjophthalmol-2019-315482. doi: 10.1136/bjophthalmol-2019-315482. [Epub ahead of print] PubMed PMID:31949095.
117. **Parravano M**, Costanzo E, Borrelli E, Sacconi R, Virgili G, Sadda SR, Scarinci F, Varano M, Bandello F, Querques G. Appearance of cysts and capillary non perfusion areas in diabetic macular edema using two different OCTA devices. *Sci Rep*. 2020 Jan 21;10(1):800. doi: 10.1038/s41598-020-57680-w.
118. **Parravano M**, Costanzo E, Querques G. Profile of non-responder and lateresponder patients treated for diabetic macular edema: systemic and ocular factors. *Acta Diabetol*. 2020 Feb 29. doi: 10.1007/s00592-020-01496-7. [Epub ahead of print] Review. PubMed PMID: 32114642.
119. Eandi CM, De Geronimo D, Giannini D, Polito MS, Tosi GM, Neri G, Le Mer Y, Varano M, **Parravano M**. Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants. *Acta Diabetol*. 2020 Feb 29. doi: 10.1007/s00592-020-01504-w. [Epub ahead of print] PubMed PMID: 32114643.
120. **Parravano M**, Scarinci F, Parisi V, Giorno P, Giannini D, Oddone F, Varano M. Citicoline and Vitamin B(12) Eye Drops in Type 1 Diabetes: Results of a 3-year Pilot Study Evaluating Morpho-Functional Retinal Changes. *Adv Ther*. 2020 Apr;37(4):1646-1663. doi: 10.1007/s12325-020-01284-3. Epub 2020 Mar 16. PubMed PMID: 32180131.
121. Virgili G, **Parravano M**, Gatta G, Capocaccia R, Mazzini C, Mallone S, Botta L; RARECAREnet Working Group. Incidence and Survival of Patients With Conjunctival

- Melanoma in Europe. *JAMA Ophthalmol.* 2020 Mar 26;138(6):601-8. doi: 10.1001/jamaophthalmol.2020.0531. Online ahead of print.
122. Ziccardi L, Landi D, De Geronimo D, Barbano L, Giorno P, Marfia GA, Albanese M, Parisi V, **Parravano M**. Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography. *J Neuroophthalmol.* 2020 Mar 24. doi: 10.1097/WNO.0000000000000937. [Epub ahead of print] PubMed PMID: 32235227.
123. Toto L, Evangelista F, Viggiano P, Erroi E, D'Onofrio G, Libertini D, Porreca A, D'Aloisio R, **Parravano M**, Di Antonio L, Di Nicola M, Mastropasqua R. Corrigendum to "Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy". *Biomed Res Int.* 2020 Jul 1;2020:6219089. doi: 10.1155/2020/6219089. eCollection 2020.
124. Parisi V, Ziccardi L, Costanzo E, Tedeschi M, Barbano L, Manca D, Di Renzo A, Giorno P, Varano M, **Parravano M**. Macular Functional and Morphological Changes in Intermediate Age-Related Maculopathy. *Invest Ophthalmol Vis Sci.* 2020 May 11;61(5):11. doi: 10.1167/iovs.61.5.11.
125. Fallico M, Avitabile T, Castellino N, Longo A, Russo A, Bonfiglio V, Parisi F, Furino C, Panozzo G, Scoria V, Carnevali A, Bandello F, Parodi MB, Cennamo G, Cillino S, Vadalà M, Sunseri Trapani V, Cagini C, Fiore T, Lupidi M, **Parravano M**, Varano M, Giorno P, Boscia F, Giancipoli E, Eandi C, Le Mer Y, Reibaldi M. Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study. *Acta Ophthalmol.* 2020 Jun 26. doi: 10.1111/aos.14516. Online ahead of print.
126. Scarinci F, Patacchioli FR, Ghiciuc CM, Pasquali V, Bercea RM, Cozma S, Parravano M. Psychological Profile and Distinct Salivary Cortisol Awake Response (CAR) in Two Different Study Populations with Obstructive Sleep Apnea (OSA) and Central Serous Chorioretinopathy (CSC). *J Clin Med.* 2020 Aug 3;9(8):2490. doi: 10.3390/jcm9082490.
127. Toto L, D'Aloisio R, Chiarelli AM, Di Antonio L, Evangelista F, D'Onofrio G, Merla A, Parravano M, Di Marzio G, Mastropasqua R. A Custom-Made Semiautomatic Analysis of Retinal Nonperfusion Areas After Dexamethasone for Diabetic Macular Edema. *Transl Vis Sci Technol.* 2020 Jun 11;9(7):13. doi: 10.1167/tvst.9.7.13. eCollection 2020 Jun.
128. Mastropasqua R, Evangelista F, Amodei F, D'Aloisio R, Pinto F, Doronzo E, Viggiano P, Porreca A, Di Nicola M, **Parravano M**, Toto L. Optical Coherence Tomography Angiography in Macular Neovascularization: A Comparison Between Different OCTA Devices. *Transl Vis Sci Technol.* 2020 Oct 7;9(11):6. doi: 10.1167/tvst.9.11.6. eCollection 2020 Oct.
129. Scarinci F, Picconi F, Virgili G, Varano M, Giorno P, Frontoni S, **Parravano M**. Microvascular impairment as a biomarker of diabetic retinopathy progression in the long-term follow up in type 1 diabetes. *Sci Rep.* 2020 Oct 26;10(1):18266. doi: 10.1038/s41598-020-75416-8.
130. Iacono P, Da Pozzo S, Varano M, **Parravano M**. Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy. *Pharmaceuticals (Basel).* 2020 Oct 29;13(11):E349. doi: 10.3390/ph13110349.
131. Lupidi M, Gujar R, Cerquaglia A, Chhablani J, Fruttini D, Muzi A, Corbucci R, Fiore T, Coscas F, Coscas G, **Parravano M**, Cagini C. OCT-Angiography as a reliable prognostic tool in laser-treated proliferative diabetic retinopathy: The RENOCTA Study. *Eur J Ophthalmol.* 2020 Nov 2;1120672120963451. doi: 10.1177/1120672120963451. Online ahead of print.

132. Scarinci F, Varano M, **Parravano M**. Resilience of the Photoreceptors in Posterior Multifocal Placoid Pigment Epitheliopathy Observed by Microperimetry over Time. *Ocul Immunol Inflamm.* 2020 Nov 2:1-7. doi: 10.1080/09273948.2020.1817502. Online ahead of print.
133. Borrelli E, **Parravano M**, Costanzo E, Sacconi R, Querques L, Pennisi F, De Geronimo D, Bandello F, Querques G. Using three-dimensional OCTA metrics improves repeatability on quantification of ischemia in eyes with diabetic macular edema. *Retina.* 2020 Dec 14; Publish Ahead of Print. doi: 10.1097/IAE.0000000000003077. Online ahead of print.
134. Querques G, Sacconi R, Capuano V, Carnevali A, Colantuono D, Battista M, Borrelli E, Miere A, **Parravano M**, Costanzo E, Querques L, Souied EH, Bandello F. Treatment-naïve quiescent macular neovascularization secondary to AMD: The 2019 Young Investigator Lecture of Macula Society. *Eur J Ophthalmol.* 2021 Jan 14:1120672120986370. doi: 10.1177/1120672120986370.
135. Borrelli E, Sacconi R, **Parravano M**, Costanzo E, Querques L, Battista M, Grosso D, Giorno P, Bandello F, Querques G. OCTA Assessment of the Diabetic Macula: a Comparison Study among Different Algorithms. *Retina.* 2021 Feb 11. doi: 10.1097/IAE.0000000000003145. PMID: 33587426
136. Scarinci F, Picconi F, Virgili G, Varano M, Giorno P, Frontoni S, **Parravano M**. Author Correction: Microvascular impairment as a biomarker of diabetic retinopathy progression in the long-term follow up in type 1 diabetes. *Sci Rep.* 2021 Mar 2;11(1):5399. doi: 10.1038/s41598-021-84931-1. PMID: 33654167
137. Oddone F, Rossetti L, **Parravano M**, Sbardella D, Coletta M, Ziccardi L, Roberti G, Carnevale C, Romano D, Manni G, Parisi V. Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review. *Pharmaceuticals (Basel).* 2021 Mar 20;14(3):281. doi: 10.3390/ph14030281. PMID: 33804675 Review.
138. Kodjikian L, **Parravano M**, Clemens A, Dolz-Marco R, Holz FG, Munk MR, Nicolò M, Ricci F, Silva R, Talks SJ, Verma RK, Zarranz-Ventura J, Zweifel SA. Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. *Eye (Lond).* 2021 Apr 1. doi: 10.1038/s41433-021-01487-0 PMID: 33795837 Review.
139. Sacconi R, Brambati M, Miere A, Costanzo E, Capuano V, Borrelli E, Battista M, **Parravano M**, Souied EH, Bandello F, Querques G. Characterisation of macular neovascularisation in geographic atrophy. *Br J Ophthalmol.* 2021 Apr 9:bjophthalmol-2021-318820. doi: 10.1136/bjophthalmol-2021-318820. PMID: 33836986
140. **Parravano M**, Ziccardi L, Borrelli E, Costanzo E, Frontoni S, Picconi F, Parisi V, Sacconi R, Di Renzo A, Varano M, Querques G. Outer retina dysfunction and choriocapillaris impairment in type 1 diabetes. *Sci Rep.* 2021 Jul 26;11(1):15183. doi: 10.1038/s41598-021-94580-z.
141. Pierluigi Iacono, Stefano Da Pozzo, Alberto Bedendo, Alessandro Arrigo, **Mariacristina Parravano**, Monica Varano, Maurizio Battaglia Parodi. Rheumatoid arthritis: an optical coherence tomography angiography study. *Eur J Ophthalmol.* 2021 Jul 27:11206721211035626. doi: 10.1177/11206721211035626. Online ahead of print.
142. Stela Vujosevic, Jose G. Cunha-Vaz, Joao Figueira, Anat Loewenstein, Edoardo Midena, **Mariacristina Parravano**, Peter Scanlon, Rafael Simó, Cristina Hernández, MH Madeira, IP Marques, AC-V Martinho, AR Santos, Olga Simó-Servat, Recivall P. Salongcay, Dinah Zur, and Tunde Peto. Standardisation of Optical Coherence Tomography Angiography Imaging

- Biomarkers in Diabetic Retinal Disease. *Ophthalmic Res.* 2021 Jul 30. doi: 10.1159/000518620. Online ahead of print.
143. Costanzo E, **Parravano M**, Giannini D, Borrelli E, Sacconi R, Querques G. Imaging Biomarkers of 1-Year Activity in Type 1 Macular Neovascularization. *Transl Vis Sci Technol.* 2021 May 3;10(6):18. doi: 10.1167/tvst.10.6.18.
  144. **Parravano M**, Petri D, Maurutto E, Lucenteforte E, Menchini F, Lanzetta P, Varano M, van Nispen RMA, Virgili G. Association Between Visual Impairment and Depression in Patients Attending Eye Clinics: A Meta-analysis. *JAMA Ophthalmol.* 2021 Jul 1;139(7):753-761. doi: 10.1001/jamaophthalmol.2021.1557.
  145. Parisi V, Ziccardi L, Barbano L, Giorno P, Varano M, **Parravano M**. Citicoline and Vitamin B<sub>12</sub> Eye Drops in Type 1 Diabetes: Results of a 36-Month Pilot Study Evaluating Macular Electrophysiological Changes. *Adv Ther.* 2021 Jul;38(7):3924-3936. doi: 10.1007/s12325-021-01771-1. Epub 2021 Jun 5.
  146. Borrelli E, Grosso D, **Parravano M**, Costanzo E, Brambati M, Viganò C, Sacconi R, Querques L, Pina A, De Geronimo D, Bandello F, Querques G. Volume rendered 3D OCTA assessment of macular ischemia in patients with type 1 diabetes and without diabetic retinopathy. *Sci Rep.* 2021 Oct 5;11(1):19793. doi: 10.1038/s41598-021-99297-7.
  147. **Parravano M**, Costanzo E, Scondotto G, Trifirò G, Virgili G. Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. *BioDrugs.* 2021 Nov;35(6):673-692. doi: 10.1007/s40259-021-00499-2. Epub 2021 Oct 16.
  148. **Parravano M**, Fragiotta S, Costanzo E, Giannini D, De Geronimo D, Viggiano P, Riccardo S, Querques G. Differences in cysts characteristics and related influence on the anatomical response after dexamethasone implant in diabetic macular oedema. *Eye (Lond).* 2021 Nov 24. doi: 10.1038/s41433-021-01857-8. Online ahead of print.
  149. Scarinci F, Patacchioli FR, Costanzo E, **Parravano M**. Relationship of Choroidal Vasculature and Choriocapillaris Flow With Alterations of Salivary  $\alpha$ -Amylase Patterns in Central Serous Chorioretinopathy. *Invest Ophthalmol Vis Sci.* 2021 Dec 1;62(15):19. doi: 10.1167/iovs.62.15.19.
  150. Corbelli E, Sacconi R, Battista M, Bacherini D, Miere A, Borrelli E, Costanzo E, Vella G, **Parravano M**, Ziccardi L, Sodi A, Rizzo S, Souied EH, Bandello F, Querques G. Choroidal vascularity index in eyes with central macular atrophy secondary to age-related macular degeneration and Stargardt disease. *Graefes Arch Clin Exp Ophthalmol.* 2022 Jan 20. doi: 10.1007/s00417-021-05337-3. Online ahead of print.
  151. **Parravano M**, Allegrini D, Carnevali A, Costanzo E, Giannaccare G, Giorno P, Scorcìa V, Spedicato GA, Varano M, Romano MR. Effectiveness of a Hydrophilic Curcumin-Based Formulation in Coadjuvating the Therapeutic Effect of Intravitreal Dexamethasone in Subjects With Diabetic Macular Edema. *Front Pharmacol.* 2022 Jan 4;12:726104. doi: 10.3389/fphar.2021.726104. eCollection 2021.
  152. Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. *Lancet.* 2022 Jan 21;S0140-6736(22)00010-1. doi: 10.1016/S0140-6736(22)00010-1. Online ahead of print.

153. Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. *Lancet*. 2022 Jan 21;S0140-6736(22)00018-6. doi: 10.1016/S0140-6736(22)00018-6. Online ahead of print.
154. Udaondo P, **Parravano M**, Vujosevic S, Zur D, Chakravarthy U. Update on Current and Future Management for Diabetic Maculopathy. *Ophthalmol Ther*. 2022 Jan 31. doi: 10.1007/s40123-022-00460-8. Online ahead of print.

### ***Books & Book Chapters***

Chapter: “Ruolo dei beta bloccanti in oftalmologia”. *Oftalmografia* n 1/2005. Manni G, Centofanti M, Cupo G, Oddone F, Parravano M.

Chapter: “La terapia medica: i farmaci che riducono la formazione di umor acqueo”. *Il Glaucoma*. Ed. Stefano Gandolfi. Mattioli 1885.

Chapter: “Application of Rheopheresis in Ophthalmology” *La Dialisi: tecnica e clinica*. Ed Società Editrice Universo 2007. C.U. Casciani, V. Cervelli, S. De Angelis, G. Splendiani.

Contribution to the drafting of Italian Guidelines for AMD-Fondazione G.B.Bietti-IRCCS 2008

Chapter: *Essential in Ophthalmology*, Dr Holz, 2009 title: “OCT vs. photography for diagnosis of diabetic macular edema”; Gianni Virgili, MD, Francesca Menchini, MD, Mariacristina Parravano, MD

Health Technology Assessment of Lucentis in the AMD treatment. *JPH-Year 7, Volume 6, Number 2, Suppl. 3, 2009*

Contribution to the drafting of management of retinal vein occlusions–IRCCS San Raffaele Milano/Fondazione G.B.Bietti-IRCCS 2010

Chapter: “Disorders of vitreoretinal Interface” Varano M, Parravano M, De Geronimo D. Springer Editor 2014

Chapter:” Role of imaging on diagnosis and treatment of diabetic retinopathy”. *Minerva Oftalmologica* June 2018, Vol 60 num 2

Chapter:” OCT Angiography in diabetic retinopathy”. *Minerva Oftalmologica* 2018

Contribution to the book: “Anatomical biomarkers in neovascular AMD”. Springer Healthcare Italia Srl. 2020

Roma 18 Gennaio 2022

Mariacristina Parravano